Athersys, Inc. (ATHX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Athersys Reports Second Quarter 2014 Results
August 11, 2014 4:05 PM EDTCLEVELAND, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) today announced its financial results for the three months ended June 30, 2014. Highlights of the second quarter of 2014 and recent events include:
Advanced enrollment of Phase 2 clinical trial of MultiStem® cell therapy for treatment of ischemic stroke, expecting to complete enrollment in the next several months with initial top-line results following analysis of patient data collected through 90 days after treatment; Progressed preparations for Phase 2 acute myocardial infarction (AMI) study targeted to be launched later this year; Continued interactions with Pfizer regarding the... More